Monoamine Oxidase Inhibitors (MAOIs) The concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine, or linezolid, may manifest as serotonin syndrome, or opioid toxicity (e.g., respiratory depression, coma) [see WARNINGS]
In certain circumstancessuch as pregnancy, concurrent illness, or rapid metabolic turnoverB12 requirements may increase, and dosing adjustments may be necessary under medical supervision
There is no UK Summary of Product Characteristics (SmPC) for retatrutide, and no authorised clinical dosing or reconstitution guidance exists
At the same time, a gray market of research peptides sold online is leading people to experiment with peptides without understanding the risks
Added to cart View cart Researchers often pair GHK-Cu with these compounds for multi-system protocols